Description: NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Home Page: www.neubasetherapeutics.com
NBSE Technical Analysis
350 Technology Drive
Pittsburgh,
PA
15219
United States
Phone:
646 450 1790
Officers
| Name | Title |
|---|---|
| Dr. Dietrich A. Stephan Ph.D. | Founder, CEO & Director |
| Mr. Todd P. Branning | CFO & Sec. |
| Dr. Curt Bradshaw Ph.D. | Chief Scientific Officer |
| Mr. Alan Scrivner J.D. | Gen. Counsel |
| Ms. Shannon McCarthy | Chief People Officer |
| Dr. Robert J. Zamboni Ph.D. | Chief of Preclinical Devel. & Member of Scientific Advisory Board |
| Dr. Ron Sarkar M.B.A., Ph.D. | Sr. VP of Corp. Strategy & Bus. Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2238 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2007-05-01 |
| Fiscal Year End: | September |
| Full Time Employees: | 37 |